Antifungals to treat Candida albicans

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 12, 2010, Pages 2037-2048

  Moudgal, Varsha ^a   Sobel, Jack ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 flucytosine; Amphotericin B; Anidulafungin; Antifungals; Antimetabolite; Azoles; C. albicans; Caspofungin; Echinocandins; Fluconazole; Itraconazole; Liposomal amphotericin B; Micafungin; Polyenes; Posaconazole; Voriconazole

Indexed keywords

2,2' ANHYDRO 5 FLUOROCYTOSINE ARABINOSIDE; ALBACONAZOLE; AMINOCANDIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIMETABOLITE; POLYENE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTHRITIS; BLADDER IRRIGATION; BONE MARROW SUPPRESSION; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CANDIDURIA; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; CYSTITIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; ESOPHAGUS CANDIDIASIS; FEVER; FLUSHING; FOOD DRUG INTERACTION; FOOT EDEMA; FUNGAL ENDOCARDITIS; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFECTION PREVENTION; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OROPHARYNX CANDIDIASIS; OSTEOMYELITIS; PACEMAKER; PHOTOPSIA; PROSTHESIS INFECTION; PYELONEPHRITIS; RETINITIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VAGINA CANDIDIASIS; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; ANTIMETABOLITES; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; ECHINOCANDINS; HUMANS; POLYENES; TREATMENT OUTCOME;

EID: 77954765564     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.493875     Document Type: Review

References (97)

1. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005;41(Suppl 6):S389-93
2. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317
3. Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:S3-14
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
5. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-1239
6. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-630
7. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96
8. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-643
9. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-291
10. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008;47:226-235
11. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. Curr Clin Pharmacol 2007;2:37-58
12. Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006;57:1153-1160
13. Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002;46:3719-3723
14. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535
15. Drew RH, Arthur RR, Perfect JR. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 2005;40:1465-1470
16. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-618
17. Bowden RA, Cays M, Gooley T, et al. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-1215
18. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396
19. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002;35:891-895
20. Anaissie E, Paetznick V, Proffitt R, et al. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991;10:665-668
21. Johnson EM, Ojwang JO, Szekely A, et al. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998;42:1412-1416
22. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003;37:415-425
23. Agustin J, Lacson S, Raffalli J, et al. Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases. Clin Infect Dis 1999;29:686-687
24. Alvarez-Lerma F, Mariscal F, Quintana E, et al. Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study. J Chemother 2009;21:330-337
25. Stiller RL, Bennett JE, Scholer HJ, et al. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982;22:482-487
26. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10-27
27. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-1330
28. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-289
29. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-176
30. Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178-180
31. Akler ME, Vellend H, McNeely DM, et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995;20:657-664
32. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995;39:40-44
33. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-1313
34. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-344
35. Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fluconazole- refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999;15:1413-1417
36. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-566
37. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002;42:395-402
38. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-732
39. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-47
40. Varma D, Thaker HR, Moss PJ, et al. Use of voriconazole in candida retinitis. Eye (Lond) 2005;19:485-487
41. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996;40:1948-1949
42. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998;31:297-300
43. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998;42:3018-3021
44. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:575-577
45. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-3154
46. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-1442
47. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22:651-655
48. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-1454
49. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-637
50. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-211
51. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-222
52. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-220
53. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347
54. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359
55. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-1186
56. Pfaller MA, Messer SA, Boyken L, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004;42:3137-3141
57. Beale M, Queiroz-telles F, Banhegyi D, et al. Randomized, double blind study of the safety and antifungal activity of ravuconzole relative to fluconazole in esophageal candidiasis. Abstract J-1621, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001. p. 392
58. Marino M, Mummanemi V, Norton J, et al. Ravuconazole exposure-response relationship in HIV+ patients with oropharyngeal candidiasis. Abstract J- 1622, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001. p. 393
59. Ramos G, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999;44:283-286
60. Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. Abstract M722, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC; 2005
61. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
62. Mouton J, Verweij P, Warn P. In Vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibility. Abstract P-021, Trends in Medical Mycology; Berlin, Germany; 2005
63. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007;51:1818-1821
64. Viljoen J, Mitha I, Heep M. Efficacy, safety and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. Abstract LB2-32, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC; 2005
65. Barchiesi F, Schimizzi AM, Fothergill AW, et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18:302-304
66. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-2332
67. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemothe 2005;49:3616-3623
68. Brown SD, Traczewski MM. Caspofungin disk diffusion breakpoints and quality control. J Clin Microbiol 2008;46:1927-1929
69. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years o global surveillance. J Clin Microbiol 2008;46:150-156
70. Ramesh M, Bhaskaran I, Ganesan L, et al. Postantifungal effect of older and newer antifungal agents on Aspergillus fumigatus and Candida albicans. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001
71. Bachmann SP, VandeWalle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002;46:3591-3596
72. Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies Antimicrob Agents Chemother 2002;46:3634-3636
73. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for th treatment of esophageal candidiasis. Am J Med 2002;113:294-299
74. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double- blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-1535
75. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002;46:451-457 (Pubitemid 34087195)
76. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029
77. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36:1445-1457
78. Liu KH, Wu CJ, Chou CH, et al. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol 2004;42:5950-5953
79. Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004;39:1253-1254
80. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005;41:e27-8
81. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007;44:e46-9
82. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003;12:1313-1333
83. Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002;51:247-255
84. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475-481
85. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-849
86. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005;21:899-907
87. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-1527
88. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-893
89. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43:215-222
90. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009;47:1942-1946
91. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770-775
92. Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008;48:304-309
93. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-2482
94. Moore C, Denning D. In vitro activity of HMR3270 against candida spp. Abstract F-2147, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001
95. Lowther J, Schio L, Platel D. In vivo efficacy of HMR3270, a new candin antifungal agent in a mouse model of candidiasis. Abstract F-2149, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 2001
96. Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades. Mycoses 2009. [Epub ahead of print]
97. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009;64:354-356